Dalton Smart
Directeur Général chez HARPOON THERAPEUTICS, INC.
Fortune : 578 828 $ au 30/04/2024
Postes actifs de Dalton Smart
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MERCK & CO., INC. | Comptroller/Controller/Auditor | 04/12/2023 | - |
| Corporate Officer/Principal | 01/09/2023 | 04/12/2023 | |
| HARPOON THERAPEUTICS, INC. | Directeur Général | - | - |
| Junior Achievement of New Jersey, Inc. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Dalton Smart
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Director/Board Member | 1 |
| Comptroller/Controller/Auditor | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Junior Achievement of New Jersey, Inc. | |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- Dalton Smart
- Expérience